Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke

Inclusion Criteria: * Age: 18 - 75 years. * Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect, confirmed by CT or MRI scan. * Clinical diagnosis of "Qixu-Xueyu Zheng" (Qi deficiency and Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales in ischemic stroke on both "Qixue" and "Xueyu" ≥ 7. * 15 days to 60 days after onset of symptoms. * Clinical diagnosis of cerebral anterior circulation obstruction. * 4≤NIHSS\<20. * Patient is willing to participate voluntarily and to sign a written patient informed consent. Exclusion Criteria: * Transient ischemic attack * Evidence of intracranial hemorrhage (ICH) in 6 months * Evidence of other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT or MRI scan. * Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months. * Woman who is under menstrual period. * Known history of allergy or suspected allergic to these chinese herbs. * Complicated with atrial fibrillation. * Fasting blood glucose ≥8 mmol / l under the treatment of diabetes or complicated with severe cardio-cerebrovascular diseases (eg. hyperlipemia, coronary heart disease with angina attack ≥ 4 times a day). * Liver function impairment with the value of ALT or AST over 1.5-fold of normal value. * Renal dysfunction with the value of serum creatinine over normal value. * Prior disable patients or complicated with osteoarthropathy that influence the motor function of the limbs. * With mental disorder that can not cooperate with doctor * Suspected addicted into alcohol or drug abuse. * With severe complications that would make the condition more complicated assessed by the investigator. * Patient who is participating in other trials or has been participated in other trials in recent 3 months.